Baird analyst Peter Arment downgrades Maxar Technologies (NYSE:MAXR) from Outperform to Neutral and raises the price target from $45 to $53.
What’s Going On With Eli Lilly Stock Wednesday?
Eli Lilly's shares surge 25% YTD to $700 billion enterprise value. Mounjaro and Zepbound drive growth with tirzepatide. BMO Capital projects $12.78 billion FY2024 tirzepatide revenues.